Literature DB >> 27327615

Smoking, alcohol and illicit drug use effects on survival in HIV-positive persons.

Kathy Petoumenos1, Matthew G Law.   

Abstract

PURPOSE OF REVIEW: In the era of effective antiretroviral therapy, HIV-positive patients experience an increase in non-AIDS associated comorbidities. Causes of death are now more frequently associated with ageing and smoking; alcohol and drug use are strongly linked to many of these causes. RECENT
FINDINGS: An almost equal life expectancy among HIV-positive people compared with HIV-negative population has been recently reported. However, life expectancy is reduced among HIV-positive smokers by at least 16 years and further reduced for people who have a history of excessive alcohol and drug use. Cohort studies report between a 1.5- and two-fold or greater increased mortality risk as a result of smoking. In a Danish population study, 61% of deaths in HIV-positive people were associated with smoking. Excessive alcohol and drug use are also elevated among specific HIV subpopulations and significantly impact morbidity and mortality. In the Veteran Affairs cohort study, moderate and excessive alcohol use increased mortality by 25-35% compared with low alcohol use.
SUMMARY: Despite the effective therapy, smoking, alcohol and drug use have a significant role in increased mortality and reduced life expectancy among HIV-positive people. These factors need to be in continued focus for the management and care of HIV-positive people.

Entities:  

Mesh:

Year:  2016        PMID: 27327615     DOI: 10.1097/COH.0000000000000306

Source DB:  PubMed          Journal:  Curr Opin HIV AIDS        ISSN: 1746-630X            Impact factor:   4.283


  19 in total

1.  Improved clinical outcomes among persons with HIV who quit smoking.

Authors:  Su Fen Lubitz; Alex Flitter; Rebecca L Ashare; Morgan Thompson; Frank Leone; Robert Gross; Robert Schnoll
Journal:  AIDS Care       Date:  2019-12-17

2.  Patterns of social determinants of health associated with drug use among women living with HIV in Canada: a latent class analysis.

Authors:  Mostafa Shokoohi; Greta R Bauer; Angela Kaida; Carmen H Logie; Ashley Lacombe-Duncan; M-J Milloy; Elisa Lloyd-Smith; Allison Carter; Mona Loutfy
Journal:  Addiction       Date:  2019-03-12       Impact factor: 6.526

3.  Placebo-controlled randomized clinical trial testing the efficacy and safety of varenicline for smokers with HIV.

Authors:  Rebecca L Ashare; Morgan Thompson; Katrina Serrano; Frank Leone; David Metzger; Ian Frank; Robert Gross; Anita Hole; Karam Mounzer; Ronald G Collman; E Paul Wileyto; Robert Schnoll
Journal:  Drug Alcohol Depend       Date:  2019-05-07       Impact factor: 4.492

4.  Preface to special collection of articles on interventions for promoting smoking cessation among individuals with HIV.

Authors:  Annette Kaufman; Joseph T Ciccolo; Rick A Berzon; E Jennifer Edelman
Journal:  Contemp Clin Trials       Date:  2021-08-13       Impact factor: 2.226

5.  Mortality among clients in the New York city HIV Care Coordination Program (CCP): incidence and associated clinical factors.

Authors:  McKaylee M Robertson; Mary K Irvine; Katherine Penrose; Graham Harriman; Sarah L Braunstein; Denis Nash
Journal:  Ann Epidemiol       Date:  2021-10-08       Impact factor: 3.797

6.  Correlates of varenicline adherence among smokers with HIV and its association with smoking cessation.

Authors:  Mackenzie Hosie Quinn; Anna-Marika Bauer; Alex Flitter; Su Fen Lubitz; Rebecca L Ashare; Morgan Thompson; Frank Leone; Robert Gross; Robert Schnoll
Journal:  Addict Behav       Date:  2019-10-22       Impact factor: 3.913

7.  Tobacco Harm Reduction with Vaporised Nicotine (THRiVe): The Study Protocol of an Uncontrolled Feasibility Study of Novel Nicotine Replacement Products among People Living with HIV Who Smoke.

Authors:  Stephanie Bell; Judith Dean; Charles Gilks; Mark A Boyd; Lisa Fitzgerald; Allyson Mutch; Peter Baker; Graham Neilsen; Coral E Gartner
Journal:  Int J Environ Res Public Health       Date:  2017-07-18       Impact factor: 3.390

8.  Dissecting the Role of Disturbed ER-Golgi Trafficking in Antivirals and Alcohol Abuse-Induced Pathogenesis of Liver Disorders.

Authors:  Cheng Ji
Journal:  J Drug Abuse       Date:  2017-09-26

9.  Prevalence of self-reported comorbidities in HIV positive and HIV negative men who have sex with men over 55 years-The Australian Positive & Peers Longevity Evaluation Study (APPLES).

Authors:  Kathy Petoumenos; Robin Huang; Jennifer Hoy; Mark Bloch; David J Templeton; David Baker; Michelle Giles; Matthew G Law; David A Cooper
Journal:  PLoS One       Date:  2017-09-08       Impact factor: 3.240

10.  Is substance use associated with HIV cascade outcomes in Latin America?

Authors:  Raquel B De Boni; Meridith B Peratikos; Bryan E Shepherd; Beatriz Grinsztejn; Claudia Cortés; Denis Padgett; Eduardo Gotuzzo; Pablo F Belaunzarán-Zamudio; Peter F Rebeiro; Stephany N Duda; Catherine C McGowan
Journal:  PLoS One       Date:  2018-03-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.